Key takeaway: Aarti Pharmalabs Limited submitted its Q1 FY27 Results Presentation, highlighting its position as a leading manufacturer of generic APIs and Xanthine derivatives. The company reported over 220 products and 63 patents filed, with a global market share in Xanthine estimated at 15-20%. The presentation detailed the company's operational revenue of INR 5,346 million for Q1 FY27, reflecting a 42.4% year-on-year increase. EBITDA for the same period was INR 1,327 million, with an EBITDA margin of 24.82%. The company emphasized its strong regulatory compliance, with multiple USFDA and EU GMP accreditations. Aarti Pharmalabs also outlined its strategic initiatives, including a planned investment of INR 149 crores for capacity expansion at its Atali Block. The document noted a focus on R&D investments to enhance product capabilities and a goal of achieving a revenue and EBITDA CAGR of 15-18% over the next 3-4 years.

Key takeaway: Management reported that Aarti Pharmalabs Limited achieved a revenue of Rs.580 Crores for Q4 FY2026, reflecting a 9% year-on-year increase. For the full year FY2026, revenue was Rs.1798 Crores, slightly up from Rs.1771 Crores in FY2025. EBITDA for Q4 FY2026 was Rs.134 Crores, down from Rs.141 Crores in the previous year, while full-year EBITDA was Rs.406 Crores compared to Rs.428 Crores in FY2025. The profit after tax for Q4 FY2026 was Rs.62 Crores, down from Rs.89 Crores a year prior, and for the full year, it was Rs.176 Crores compared to Rs.257 Crores in FY2025. Management highlighted that the Xanthine derivative segment recorded its highest quarterly revenue, contributing 43% to turnover. They also discussed ongoing expansion projects and investments, including Rs.400 Crores planned for FY2027. Management set a goal of 15% to 18% growth in revenue and EBITDA over the next few years.

Key takeaway: Aarti Pharmalabs Limited submitted its Q4 FY26 Results Presentation to the BSE and NSE on May 26, 2026. The presentation highlighted the company's extensive portfolio, including over 220 products and 63 patents filed. Aarti Pharmalabs is recognized as a leading manufacturer of generic APIs and Xanthine derivatives, with a global market share of 15-20% in Xanthine. The company operates seven manufacturing units, three of which are USFDA approved, and has over 500 global clients across more than 50 countries. Financially, the standalone revenue for FY26 was reported at INR 17,976 million, reflecting a 1.5% year-on-year increase. However, the EBITDA margin decreased to 22.59% from 24.08% in FY25. The company also reported a PAT of INR 1,762 million for FY26, down 31.5% from the previous year. The presentation included details on ongoing capacity expansions and strategic initiatives for future growth.

Key takeaway: Aarti Pharmalabs Limited held its earnings conference call on February 10, 2026, to discuss its financial results for the third quarter and nine months of FY26. Management reported a revenue of INR 425 crores, down from INR 471 crores in the previous year, with EBITDA at INR 103 crores compared to INR 115 crores. The profit after tax was INR 44 crores, a decrease from INR 74 crores year-on-year. The company operates in three segments: Xanthine Derivatives, API and Intermediates, and CDMO/CMO services, with Xanthine Derivatives contributing 49% of turnover. Management noted challenges in the API segment due to margin pressures and delays in project deliveries affecting CDMO revenue guidance. The Atali plant faced initial operational challenges, but corrective actions are in place. Management expressed confidence in long-term growth despite near-term pressures, emphasizing efforts to enhance operational efficiencies and shareholder value.

Key takeaway: Aarti Pharmalabs Limited submitted its Q3-FY26 Results Presentation to the BSE and NSE on February 10, 2026. The presentation highlighted the company's extensive product portfolio, with over 220 products and 62 patents filed. Aarti Pharmalabs operates seven manufacturing units, including three USFDA-approved facilities, and serves over 500 global clients across more than 50 countries. The company reported a standalone revenue of INR 4,253 million for Q3-FY26, reflecting a 1.9% increase quarter-on-quarter but a 9.7% decrease year-on-year. EBITDA for the same period was INR 1,030 million, with an EBITDA margin of 24.22%. The presentation also noted ongoing capacity expansions in the Xanthine derivatives segment and operational challenges at the Atali greenfield site. Management emphasized a focus on regulatory compliance and strategic growth initiatives.